Imatinib Induced Delayed and Refractory Generalized Fluid Retention: A Case Report and Review of Literature
Journal Title: Biomedical Journal of Scientific & Technical Research (BJSTR) - Year 2019, Vol 19, Issue 1
Abstract
Imatinib is a tyrosine kinase inhibitor used mainly for ABL-BCR positive CML. Development of fluid retention(FR) following imatinib therapy is the most common side effect. However, sever FR as generalized anasarca, pleural effusion, ascites, and pericardial effusion are not common events during imatinib treatment. We report a case of CML treated with imatinib for long time then presented with sever generalized FR. After exclusion of other causes of generalized FR we stop imatinib but there was no improvement of the conditions. So, mild FR resulted from imatinib may pass to chronic state and become refractory to treatment and should be treated as early as possible. The molecular targeted therapy started with introduction of tyrosine kinase inhibitor (Imatinib) that selectively inhibit phosphorylation of BCR-ABL protein with subsequent inhibition of growth of BCR-ABL positive cells [1]. Imatinib was approved in 2001 as a first targeted therapy for treatment of BCR-ABL positive chronic myeloid leukemia (CML) and in 2003 for treatment of ckit or CD 117 positive gastrointestinal stromal tumor (GIST) [2,3]. The safety and efficacy profiles of imatinib were explored in the last decades and have been well known, the most common reported side effect and dose limiting toxicity of imatinib was fluid retention (FR) [4]. Manifestations of FR usually presented as mild periorbital and/or lower limbs (LLs) edema that was easily manageable [5]. Development of sever FR manifested by marked subcutaneous and LLs edema, ascites, pleural and pericardial effusions were less frequently seen with imatinib treatment [6]. Due to rarity of imatinib induced sever FR, we reported this case of imatinib induced marked FR presented after long time of imatinib treatment and was refractory to drug withdrawal and conventional treatment.
Authors and Affiliations
Bader A Abdelmaksoud, Yaser Gad, Fayez G Alruwaily
Keywords
Related Articles
- EP ID EP622731
- DOI 10.26717/BJSTR.2019.19.003233
- Views 163
- Downloads 0
Are You Ready to Take Your Drug Product from Phase I Studies to the Subsequent Phases?
Building a safety assessment package to go into the Phase I clinical stage sounds simple enough. All the steps pertaining to preclinical testing, pharmaceutical development, clinical supplies manufacturing, and regulator...
Assessment of the Knowledge, Attitude and Practice about Food Safety among Saudi Population in Taif
Foodborne diseases outbreaks continue to be problem indicating the failure of population to adhere to safe practices during food preparation. Thus, this study aimed to assess the knowledge, attitude, and practices (KAP)...
Powered Stapling Platforms in Laparoscopic Liver Resection
Introduction: The most recent innovation in laparoscopic surgery has been the introduction of powered stapler platforms. These systems were designed to standardize staple formation, by minimizing tissue dissection and co...
Association of Positive Results of Single Serum Biomarker with the Clinical Parameters
Background: Many serum biomarkers have been developed to diagnose cancers at an early stage and monitor drug therapy. At present, the most common clinical used serum-tumor biomarkers are mainly including Alpha-Fetop...
Prenatal Diagnosis of Dystrophin Gene Mutations using Multiplex Ligation Dependent Probe Amplification (MLPA) for Duchene Muscular Dystrophy
Duchene muscular dystrophy (DMD) is a common X-chromosomal recessive disorders caused by mutations in the dystrophin gene. Male children are primarily affected by the disease, characterized by progressive muscular wastin...